Observed relationship between rituximab pharmacokinetic parameters, (A) rituximab elimination half-life (T_1/2β) and (B) area under the concentration-time curve (AUC₁), relative to TMTV₀. See Figure 2 in the article by Tout et al that begins on page 2616.